https://www.skyrizihcp.com/rheumatology/dosing SKYRIZI 150 mg/mL Pen Injection Training Video https://skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resource-video-thumbnail-1.png After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6299406363001 426 SKYRIZI 150 mg/mL Prefilled Syringe Injection Training Video https://skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resource-video-thumbnail-2.png After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6299406364001 370 https://www.skyrizihcp.com/rheumatology/support/forms-downloads SKYRIZI 150 mg/mL Pen Injection Training Video https://skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resource-video-thumbnail-1.png After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6299406363001 426 SKYRIZI 150 mg/mL Prefilled Syringe Injection Training Video https://skyrizihcp.com/content/dam/skyrizihcpivy/images/SKZD-ITS-0525/resource-video-thumbnail-2.png After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6299406364001 370 https://www.skyrizihcp.com/rheumatology/video-library SKYRIZI IN BIO-NAÏVE PATIENTS https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/rheumatology/SKZR-ITS-0429/Patient-Types-Thumbnail.png Dr. Schwartzman and Dr. Khattri define how a bio-naïve patient may present in clinical practice and review the demographics of the patient population evaluated in the KEEPsAKE 1 PsA trial. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6308722136112 609 EFFICACY AND SAFETY RESULTS WITH SKYRIZI https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/rheumatology/SKZR-ITS-0429/Patient-Identification-Thumbnail.png Dr. Schwartzman and Dr. Khattri review the clinical efficacy endpoints from the PsA trials, including ACR20/50/70, ACR components such as patient-reported pain, and enthesitis and dactylitis, then conclude with a discussion of SKYRIZI's safety profile across 2 indications. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6308721803112 812 https://www.skyrizihcp.com/rheumatology/patient-identification SKYRIZI IN BIO-NAÏVE PATIENTS https:/www.skyrizihcp.com/content/dam/skyrizihcpivy/images/rheumatology/SKZR-ITS-0429/Patient-Types-Thumbnail.png To better inform decisions around PsA treatment selection in clinical practice, it’s important to identify where in their disease progression a patient may be and what their treatment goals are. Watch Dr. Schwartzman and Dr. Khattri identify how a bio-naïve patient may present in clinical practice and give an overview of the demographics of the patient population in the KEEPsAKE 1 PsA trial. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6312770019112 609 https://www.skyrizihcp.com/rheumatology/acr-data EFFICACY AND SAFETY RESULTS WITH SKYRIZI https://www.skyrizihcp.com/content/dam/skyrizihcpivy/images/rheumatology/SKZR-ITS-0429/Patient-Identification-Thumbnail.png Dr. Schwartzman and Dr. Khattri review the clinical efficacy endpoints from the PsA trials, including ACR20/50/70, ACR components such as patient-reported pain, and enthesitis and dactylitis, then follow with a discussion of SKYRIZI's safety profile across 2 indications. https://players.brightcove.net/1029485116001/Mcp9TXMkPT_default/index.html?videoId=6312770018112 812